We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Global Microfluidic Immunoassay Market to Reach USD 2 Billion by 2025

By LabMedica International staff writers
Posted on 01 Oct 2019
Print article
Image: In 2019, lab-on-a-chip/microfluidic diagnostics is expected to grow at the fastest CAGR, owing to its capability for scaling down whole lab processes on a single chip and expediting the process of disease diagnosis with highly precise quantitative results (Photo courtesy of Fotolia).
Image: In 2019, lab-on-a-chip/microfluidic diagnostics is expected to grow at the fastest CAGR, owing to its capability for scaling down whole lab processes on a single chip and expediting the process of disease diagnosis with highly precise quantitative results (Photo courtesy of Fotolia).
The global microfluidic immunoassay market is expected to grow at a CAGR of 12.7% from 2019 to USD 2.0 billion by 2025, driven by greater benefits offered by Lab-on-chip (LOC) over conventional quantifiable technologies, the growing need for point-of-care (POC) in low-resource settings, and increasing research activities in the field of microfluidic technology. The market growth will be further aided by increased venture capital funding for the development of LOC-based POC diagnostics, rapid decision-making in emergency care, and rising incidence and prevalence of chronic diseases coupled with an aging population.

These are the latest findings of Research and Markets, (Dublin, Ireland), a global market research company.

Additionally, the emerging economies and novel technologies, such as paper-based microfluidics, will also provide significant growth opportunities for the market players. However, the lengthy approval time for POC devices and reluctance among healthcare professionals to replace existing diagnostic platforms are likely to hinder market growth. Nevertheless, the selection of suitable substrate material for designing microfluidic chip, difficulty in up-scaling the process for mass production, and product-design and cost-related challenges in the developing countries will prove to be the major hurdles for market growth.

Based on product type, the adoption of LOC/microfluidic diagnostics is expected to grow at the fastest CAGR in 2019 owing to its capability for scaling down whole laboratory processes on a single chip and expediting the process of disease diagnosis with highly precise quantitative results. On the basis of technology, the non-LOC POC technologies segment is estimated to hold the largest share of the global microfluidic immunoassay market in 2019 due to increased adoption of these technologies over the years for a wide range of diagnostic applications. However, LOC POC technology is expected to grow at the fastest CAGR during the forecast period, mainly due to greater benefits offered by LOC over conventional POC diagnostic methods and growing research activities in this field that are supported by private and public funding.

Based on application, the cardiac biomarker detection segment is estimated to hold the largest share of the global microfluidic immunoassay market in 2019 and also grow at the fastest CAGR during the forecast period. The segment’s performance is expected to be driven by the high prevalence of cardiovascular diseases, availability of a large number of LOC-based products for cardiac biomarkers, and greater adoption of these products by end-users. Geographically, North America is expected to hold the largest share of the global microfluidic immunoassay market in 2019, followed by Europe, Asia-Pacific, Latin America, and Middle East & Africa.

Related Links:
Research and Markets

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.